Zukanorm M 1000mg/100mg Tablet SR is a fixed-dose combination medication containing Metformin 1000mg and Vildagliptin 100mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving insulin sensitivity, thereby enhancing peripheral glucose uptake and utilization. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases incretin levels, which inhibit glucagon release and increase insulin secretion in a glucose-dependent manner. The sustained-release (SR) formulation ensures prolonged therapeutic plasma concentrations, improving glycemic control while minimizing gastrointestinal side effects commonly associated with Metformin. Zukanorm M is prescribed as an adjunct to diet and exercise to improve glycemic parameters in patients inadequately controlled on monotherapy or lifestyle modifications alone. It is essential to monitor renal function prior to and during treatment, as Metformin is contraindicated in patients with significant renal impairment. Common adverse effects include mild gastrointestinal disturbances and, rarely, hypoglycemia when used in combination with other antidiabetic agents. This combination therapy offers a complementary mechanism of action targeting multiple pathophysiological defects in type 2 diabetes, thereby optimizing glycemic control and reducing the risk of diabetes-related complications.